Skip to main content

Table 2 Cox regression models for overall survival, recurrence-free-survival, and colostomy-free survival for patients living with HIV treated with definitive chemoradiation

From: The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

 

Overall survival (OS)

Recurrence-free Survival (RFS)

Colostomy-free Survival (CFS)

Univariate Model

Adjusted Model

Univariate Model

Adjusted Model

Univariate Model

Adjusted Model

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

HR (95%CI)

p-value

Age at diagnosis

  < 40

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

 40–59

0.78 (0.37–1.64)

0.51

0.69 (0.29–1.60)

0.39

0.65 (0.29–1.47)

0.30

0.66 (0.28–1.54)

0.34

0.99 (0.29–3.41)

0.98

0.94 (0.26–3.34)

0.92

 60+

1.44 (0.66–3.17)

0.36

1.65 (0.67–4.05)

0.28

0.60 (0.24–1.51)

0.28

0.53 (0.20–1.43)

0.21

0.87 (0.22–3.48)

0.85

0.79 (0.19–3.23)

0.74

Race/Ethnicity

 Caucasian

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

 African American

1.25 (0.82–1.89)

0.29

1.31 (0.83–2.06)

0.25

1.32 (0.79–2.18)

0.29

1.17 (0.67–2.04)

0.57

0.98 (0.47–2.01)

0.95

1.06 (0.50–2.27)

0.87

 Hispanic

0.68 (0.29–1.60)

0.38

0.69 (0.27–1.81)

0.45

0.71 (0.25–2.02)

0.52

0.65 (0.22–1.94)

0.44

0.99 (0.29–3.35)

0.99

1.17 (0.33–4.12)

0.81

Oher/Unknown

1.64 (0.80–3.33)

0.18

2.10 (0.93–4.74)

0.07

0.98 (0.35–2.77)

0.97

1.36 (0.46–4.06)

0.58

1.39 (0.41–4.71)

0.60

1.22 (0.35–4.24)

0.75

HIV Medication

 No Protease Inhibitor

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

 Protease Inhibitor

1.04 (0.68–1.59)

0.87

0.86 (0.53–1.38)

0.53

1.53 (0.86–2.72)

0.15

1.34 (0.74–2.43)

0.33

1.07 (0.52–2.23)

0.85

1.03 (0.49–2.15)

0.94

Year HIV Diagnosed

  < 2000

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

 2000–2009

0.77 (0.48–1.22)

0.26

  

0.82 (0.47–1.43)

0.48

  

1.22 (0.61–2.45)

0.58

  

 2010–2016

0.98 (0.42–2.27)

0.96

  

0.63 (0.19–2.01)

0.43

  

  

Smoker

 Never

1.00

Ref

1.00

Ref

1.00

Ref

  

1.00

Ref

  

 Former

1.76 (0.96–3.22)

0.07

1.65 (0.82–3.29)

0.16

2.01 (1.01–4.00)

0.05

  

1.14 (0.47–2.77)

0.77

  

 Current

1.45 (0.88–2.40)

0.15

1.51 (0.83–2.77)

0.18

1.12 (0.62–2.04)

0.71

  

0.60 (0.28–1.27)

0.18

  

 Unknown

2.54 (1.16–5.55)

0.02

4.08 (1.71–9.73)

< 0.01

0.97 (0.28–3.35)

0.97

  

0.84 (0.19–3.73)

0.82

  

Stage

 I

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

  

 II

2.38 (1.17–4.82)

0.02

3.16 (1.50–6.62)

< 0.01

1.75 (0.77–3.97)

0.18

1.77 (0.75–4.16)

0.19

2.06 (0.70–6.00)

0.19

  

 IIIA

2.94 (1.16–7.41)

0.02

4.63 (1.67–12.82)

< 0.01

1.88 (0.60–5.93)

0.28

2.03 (0.62–6.62)

0.24

2.71 (0.68–10.86)

0.16

  

 IIIB

3.07 (1.44–6.53)

< 0.01

3.16 (1.42–7.06)

< 0.01

3.10 (1.32–7.31)

< 0.01

3.01 (1.20–7.55)

0.02

1.98 (0.59–6.59)

0.27

  

 IV

3.83 (1.18–12.47)

0.03

2.41 (0.69–8.42)

0.17

5.73 (1.67–19.6)

< 0.01

6.14 (1.68–22.44)

< 0.01

  

 Unknown

3.66 (0.79–16.99)

0.10

0.94 (0.17–5.11)

0.94

  

CD4 at Cancer Diagnosis

  ≤ 200

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

  > 200

0.90 (0.58–1.41)

0.66

  

0.63 (0.38–1.06)

0.08

  

1.09 (0.49–2.42)

0.83

  

 Unknown

1.00 (0.41–2.47)

0.99

  

0.59 (0.17–2.01)

0.40

  

1.78 (0.46–6.93)

0.40

  

Nadir CD4 during Radiation

  ≤ 200

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

  > 200

0.74 (0.45–1.22)

0.24

  

0.75 (0.42–1.33)

0.32

  

0.88 (0.40–1.90)

0.74

  

 Unknown

2.54 (1.16–5.55)

0.76

  

0.64 (0.35–1.15)

0.13

  

0.73 (0.33–1.62)

0.43

  

BMI

  < 25

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

  

 25–29.9

0.72 (0.47–1.11)

0.14

0.49 (0.30–0.81)

< 0.01

0.84 (0.50–1.42)

0.51

0.62 (0.34–1.11)

0.11

1.09 (0.55–2.18)

0.81

  

 ≥ 30

0.39 (0.17–0.91)

0.03

0.61 (0.25–1.51)

0.29

0.30 (0.09–0.95)

0.04

0.32 (0.10–1.06)

0.06

0.22 (0.03–1.61)

0.14

  

 Unknown

1.09 (0.51–2.32)

0.82

0.76 (0.32–1.77)

0.52

0.88 (0.31–2.52)

0.82

0.71 (0.24–2.13)

0.54

1.35 (0.39–4.72)

0.63

  

Alcohol Use

 No

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

 Yes

0.93 (0.63–1.40)

0.74

  

0.69 (0.41–1.16)

0.16

  

0.85 (0.43–1.70)

0.65

  

History of prior cancer

 No

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

 Yes

0.87 (0.51–1.48)

0.60

  

0.71 (0.35–1.43)

0.33

  

0.91 (0.38–2.18)

0.83

  

Radiation Modality

 2D + 3D

1.00

Ref

1.00

Ref

1.00

Ref

  

1.00

Ref

  

 IMRT

0.65 (0.40–1.06)

0.08

0.50 (0.29–0.86)

0.01

0.70 (0.39–1.26)

0.23

  

0.59 (0.25–1.39)

0.22

  

 Unknown

0.72 (0.46–1.13)

0.15

0.60 (0.36–0.98)

0.04

0.78 (0.45–1.37)

0.39

  

0.99 (0.48–2.05)

0.97

  

Completed Radiation Treatment

 No

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

  

 Yes

0.40 (0.23–0.69)

< 0.01

0.26 (0.14–0.50)

< 0.01

0.61 (0.30–1.24)

0.17

0.44 (0.20–0.95)

0.04

1.56 (0.37–6.51)

0.54

  

Length of Radiation Treatment

  ≤ 50 days

1.00

Ref

  

1.00

Ref

1.00

Ref

1.00

Ref

1.00

Ref

  > 50 days

1.67 (1.13–2.47)

0.01

  

1.48 (0.91–2.43)

0.12

1.14 (0.66–1.97)

0.63

1.55 (0.77–3.10)

0.22

1.56 (0.77–3.17)

0.22

 Unknown

2.54 (1.16–5.55)

0.15

  

2.87 (1.11–7.39)

0.03

3.63 (1.32–9.99)

0.01

5.34 (1.94–14.71)

< 0.01

5.48 (1.93–15.55)

< 0.01

Chemotherapy Regimen

 5FU + mitomycin C

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

 5FU + cisplatin

1.39 (0.81–2.39)

0.23

  

0.84 (0.38–1.84)

0.66

  

1.91 (0.82–4.46)

0.13

  

 Other

1.07 (0.63–1.85)

0.80

  

0.92 (0.47–1.81)

0.81

  

1.44 (0.62–3.37)

0.40

  

Chemotherapy Dose Reduction

 No

1.00

Ref

  

1.00

Ref

  

1.00

Ref

  

 Yes

1.40 (0.94–2.08)

0.10

  

1.46 (0.90–2.39)

0.13

  

1.23 (0.62–2.45)

0.56

  

Hospitalization during treatment

 No

1.00

Ref

1.00

Ref

1.00

Ref

  

1.00

Ref

  

 Yes

2.05 (1.40–3.00)

< 0.01

1.92 (1.24–2.96)

< 0.01

2.05 (1.28–3.30)

< 0.01

  

1.37 (0.71–2.64)

0.35